Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Kiora Pharmaceuticals Inc. KPRX

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-10.8M
▼ 401.4% YoY
$-10.1M
▼ 217.8% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -10.8
10M20M-5M-10M
20142017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating 28.2% · Net 22.4%
-1000%-2000%-3000%
201420192025
ROE
FY2025 · ROE -51.7%
10%20%-50%-100%
201420192025
Three returns, three denominators.

Each USD of equity lost 52 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -10.1
3M6M-5M-10M
201420192025

Total assetsUSD 24.3M
EquityUSD 16.1M
CashUSD 8.7M
Current ratio5.99×

Equity funds 66% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
KPRX, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.0◌0.00.00.00.00.00.00.0◌
Operating income $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B−0.00.00.0−0.0−0.00.00.00.0−0.00.0◌◌
Net income $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EPS, diluted $−2.640.87−24.25−18.55−57.12−1.49−2.23−4.57−0.93−1.51−2.70−9.20
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−51.722.6−142.9−104.5−113.3−83.9−91.2—————
Shares out B0.000.000.010.000.010.010.000.040.020.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 48 reconciliationsAUDITED

Reconciled in 11 of the 12 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks were skipped: the balance sheet is not tagged before 2014. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image